NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.

The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.